GRPH News and Press, Graphite Bio Inc. From 03/20/23

2023-03-20 16:29:39 ET Graphite Bio press release ( NASDAQ: GRPH ): Q4 GAAP EPS of -$0.44 beats by $0.07 . As of December 31, 2022, cash, cash equivalents and investments in marketable securities totaled $283.6 million. For further details see: Graphite Bio G...

Graphite Bio, Inc. (Nasdaq: GRPH) today reported recent business progress and fourth quarter and fiscal year 2022 financial results. “As announced last month, Graphite Bio has initiated a process to evaluate strategic alternatives that may result in changes to our business strategy,&#x...

Summary Graphite Bio halted its gene editing programs after a trial was halted for safety. They are restructuring and considering strategic alternatives. Their high cash balance is now the only redeeming factor. Graphite Bio ( GRPH ) is trading at a negative enterprise...

Graphite Bio ( NASDAQ: GRPH ) gained ~10% Thursday morning, even as several Wall Street analysts quickly downgraded the gene editing company following its decision to discontinue research into sickle cell disease candidate GPH101. Bank of America downgraded the biotech to Unde...

Graphite Bio ( NASDAQ: GRPH ) would reduce the company’s workforce by ~50% as a part of corporate restructuring and will reduce cash burn. The company has decided to discontinue further development of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease ...

Graphite Bio, Inc. (Nasdaq: GRPH) today announced that it has completed a review of its business, including the status of its programs, resources and capabilities. The company has decided to discontinue further development of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease and to i...

Graphite Bio ( NASDAQ: GRPH ) was down around -9% on Wednesday after BofA Securities downgraded the stock to Neutral from Buy, with a price target of $3 (down from $7). BofA Securities analysts cited "uncertainty surrounding the development timeline" of its sickle cell candidate n...

Graphite Bio ( NASDAQ: GRPH ) sank 45% in after-hours trading on Thursday after announcing that it was voluntarily pausing a phase 1/2 study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease following a serious adverse event in the first patient treated. The bi...

Graphite Bio, Inc. (Nasdaq: GRPH) today announced it is voluntarily pausing the Phase 1/2 CEDAR study of nulabeglogene autogedtemcel (nula-cel) for sickle cell disease (SCD) due to a serious adverse event in the first patient dosed with nula-cel, and the company’s conclusion that the event...

Single-cell RNA sequencing of reticulocytes will be used to measure gene correction outcomes in sickle cell patients treated with nulabeglogene autogedtemcel (nula-cel) Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high...